Modality
ERT
MOA
CAR-T CD19
Target
LAG-3
Pathway
Amyloid
Heart Failure
Development Pipeline
Preclinical
~May 2014
→ ~Aug 2015
Phase 1
~Nov 2015
→ ~Feb 2017
Phase 2
~May 2017
→ ~Aug 2018
Phase 3
Nov 2018
→ Mar 2030
Phase 3Current
NCT03068240
320 pts·Heart Failure
2018-11→2030-03·Recruiting
320 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-03-154.0y awayPh3 Readout· Heart Failure
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P3
Recruit…
Catalysts
Ph3 Readout
2030-03-15 · 4.0y away
Heart Failure
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03068240 | Phase 3 | Heart Failure | Recruiting | 320 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| Talasotorasib | Exelixis | Preclinical | APOC3 | |
| Elracapivasertib | Kymera | Phase 3 | PRMT5 |